Search

Displaying results 2991 - 3000 of 9333 in total
  1. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15564
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus

  2. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009]. … The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).

  4. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  5. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16903
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  6. Drug

    Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16910
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  7. Drug

    Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16914
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  8. Drug

    Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16915
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  9. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16919
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  10. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics. … ), POPG (palmitoyloleoyl-phosphatidylglycerol), and palmitic acid, to create the drug [lucinactant].